Citations

Showing 10 of 107854 citations.

Surgical management of insulinoma associated with multiple endocrine neoplasia type I
Ó’Ríordáin, D. S., O’Brien, Timothy , Heerden, Jon A. van, Service, F. John, Grant, Clive S.

Mayo Clinic

World Journal of Surgery | October 31, 2004 | Volume: 18 | Issue: 4 | Pages: 488-493

10.1007/bf00353743 | PMID 7725733 Get It

AbstractInsulinoma in patients with multiple endocrine neoplasia (MEN) is a rare condition that because of its usual multicentricity presents difficulties not encountered in sporadic patients. In contrast to gastrinoma, which is the most common pancreatic neoplasm associated with MEN I, malignancy and duodenal tumors are much less common for patients with insulinomas, and excellent palliative medication is not available. Accordingly, there is a much greater reliance on surgical therapy for this group of patients. Between 1970 and 1991 a total of 19 patients had surgical treatment of MEN I‐related insulinoma. Each patient had hyperinsulinemic hypoglycemia. One patient, with extensive metastases, had unresectable disease. Of the remaining 18, there were 16 (89%) multiple pancreatic tumors. Tumors were located in the neck, body, or tail in 17 cases, 10 of whom also had tumors in the head. Pancreatic resections performed were 1 total, 12 subtotal (7 also had enucleation of tumors from the pancreatic head), and 5 limited distal resections and/or enucleation (conservative resection). There was no operative mortality. One patient developed pancreatitis, fistula, and diabetes following subtotal resection and enucleation. Postoperative cure was achieved in 17 of 18 cases. Recurrent disease occurred in 2 of 5 conservative resections compared to 0 of 12 subtotal resections, with median follow‐up times of 10.4 and 10.3 years, respectively. During the follow‐up period, four patients died, possibly all due to MEN I‐related conditions. Hyperinsulinism in MEN I is associated with the occurrence of multiple, usually benign, pancreatic islet cell tumors, and surgery is an effective treatment modality. Surgical management should be guided by two principles: total removal of gross disease and safe prophylactic pancreatic resection. Acceptable morbidity, low recurrence rates, and a low risk of inducing diabetes lead us to recommend routine subtotal distal pancreatectomy. Meticulous evaluation of the pancreatic head using intraoperative ultrasonography to locate tumors and to locate the pancreatic duct, followed by precise enucleation of residual tumors, is essential to ensure cure.
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells
Mukherjee, Pinku , Tinder, Teresa L., Basu, Gargi D. , Gendler, Sandra

Mayo Clinic

Journal of Leukocyte Biology | October 29, 2004 | Volume: 77 | Issue: 1 | Pages: 90-99

10.1189/jlb.0604333 | PMID 15513966 Get It

AbstractMUC1 (CD227) is a large transmembrane epithelial mucin glycoprotein, which is aberrantly overexpressed in most adenocarcinomas and is a target for immune therapy for epithelial tumors. Recently, MUC1 has beendetected in a variety of hematopoietic cell malignancies including T and B cell lymphomas and myelomas; however, its function in these cells is not clearly defined. Using the Jurkat T cell lymphoma cell line and normal human T cells, we demonstrate that MUC1 is not only expressed in these cells but is also phosphorylated upon T cell receptor (TCR) ligation and associates with the Src-related T cell tyrosine kinase, p56lck. Upon TCR-mediated activation of Jurkat cells, MUC1 is found in the low-density membrane fractions, where linker of T cell activation is contained. Abrogation of MUC1 expression in Jurkat cells by MUC1-specific small interfering RNA resulted in defects in TCR-mediated downstream signaling events associated with T cell activation. These include reduction in Ca2+ influx and extracellular signal-regulated kinase 1/2 phosphorylation, leading to a decrease in CD69 expression, proliferation, and interleukin-2 production. These results suggest a regulatory role of MUC1 in modulating proximal signal transduction events through its interaction with proteins of the activation complex.
Platelet-activating factor stimulates cytoplasmic alkalinization and granule acidification in human eosinophils
Bankers‐Fulbright, Jennifer L., Kephart, Gail M., Bartemes, Kathleen R. , Kita, Hirohito , O’Grady, Scott M. , Kita, H

Mayo Clinic

Journal of Cell Science | October 27, 2004 | Volume: 117 | Issue: 24 | Pages: 5749-5757

10.1242/jcs.01498 | PMID 15507482 Get It

The effects of platelet-activating factor (PAF) and IL-5 on intracellular pH were investigated in human eosinophils. Purified peripheral blood eosinophils were loaded with the ratiometric fluorescent pH indicator BCECF-AM ester. Stimulation of eosinophils with PAF produced time-dependent alkalinization of the cytoplasm from an initial pH of 7.1±0.04 to 7.5±0.05. A similar alkalinization response was produced by the calcium ionophore, ionomycin and by the calcium ATPase inhibitor, thapsigargin. These compounds as well as PAF produce significant increases in cytoplasmic calcium ([Ca2+]i). In contrast, IL-5 and the protein kinase C (PKC) activator phorbol myristate acetate (PMA) did not produce cytoplasmic alkalinization and had no effect on [Ca2+]i in eosinophils. PAF-stimulated alkalinization was not inhibited under conditions that blocked plasma membrane Na+-H+ exchange, proton channel or plasma membrane H+-ATPase activities. Measurements of intragranule pH with a cell permeant pH indicator (LysoSensor Yellow/Blue DND-160), which partitions into intracellular acidic compartments, revealed that PAF-stimulated cytosolic alkalinization correlated with intragranule acidification. These results suggest that the increase in [Ca2+]i after PAF stimulation activates a H+-ATPase present in the granule membranes, leading to enhanced granule acidification and cytoplasmic alkalinization. We propose that granule acidification is an important step in solubilization of major basic protein crystals, which are stored within the granule core, in preparation for degranulation and release of these proteins.
Analysis of Catheter-Tip (8-mm) and Actual Tissue Temperatures Achieved During Radiofrequency Ablation at the Orifice of the Pulmonary Vein
Bunch, T. Jared , Bruce, G. Keith, Johnson, Susan B., Sarabanda, Álvaro Valentim Lima , Milton, Mark A., Packer, Douglas L.

Mayo Clinic

Circulation | October 25, 2004 | Volume: 110 | Issue: 19 | Pages: 2988-2995

10.1161/01.cir.0000146905.19945.99 | PMID 15505085 Get It

Background— Many ablative approaches in or near the orifice of the pulmonary vein (PV) have demonstrated success in eliminating atrial fibrillation. Despite current practice, there are no data regarding the in vivo efficacy and safety of an 8-mm catheter tip for ablation at the PV orifice. Methods and Results— Ten mongrel dogs were studied. Thermocouples were implanted in the atrial muscle of the PV orifice. Intracardiac echocardiography monitored catheter position, tip/tissue orientation, and microbubble formation. Ninety-four ablations were performed for 120 seconds. A temperature discrepancy >10°C between the catheter tip and tissue occurred during 47 (50%) of the ablations. Despite termination of energy delivery, the average tissue temperature remained within 1°C of the achieved steady state for 9 seconds. A temperature discrepancy >10°C was more common in the right superior PV, with oblique catheter positioning, when tissue temperatures were >60°C or 80°C, and with type 1 or type 2 microbubble formation. However, microbubbles were not present in 7 (13%, type 1) and 10 (40%, type 2) ablations with tissue temperatures >80°C. The maximum tissue temperature achieved with non–full-thickness lesions was 47.3±7.4°C vs 75.9±11.7°C ( P <0.0001) for full-thickness lesions. Conclusions— Marked discrepancies between catheter-tip and tissue temperatures occurred with higher temperatures, prolonged ablation times, and unfavorable catheter thermistor–tissue contact. Also, these data suggest a conservative approach to atrial ablation, because full-thickness lesions were obtained when tissue temperatures reached 50°C to 60°C and the tissue retained high heat levels despite termination of radiofrequency energy. Finally, microbubbles are inconsistent markers of tissue overheating.
Antimicrobial Susceptibility Patterns among Viridans Group Streptococcal Isolates from Infective Endocarditis Patients from 1971 to 1986 and 1994 to 2002
Prabhu, Rajesh M. , Piper, Kerryl E., Steckelberg, James M., Wilson, Walter R. , Patel, Robin , Baddour, Larry M. , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 25, 2004 | Volume: 48 | Issue: 11 | Pages: 4463-4465

10.1128/aac.48.11.4463-4465.2004 | PMID 15504884 Get It

ABSTRACT To determine whether changes in antimicrobial resistance have occurred among viridans group streptococci, we retrospectively examined 50 viridans group streptococcal isolates recovered from patients with infective endocarditis over 3 decades. Resistance rates (percent resistant isolates 1971 to 1986 and 1994 to 2002) were as follows: levofloxacin, 0 and 9; penicillin and clindamycin, 0 and 4; and erythromycin and azithromycin, 11 and 26, respectively.
Invariant Aspartic Acid in Muscle Nicotinic Receptor Contributes Selectively to the Kinetics of Agonist Binding
Lee, Won Yong , Sine, Steven M.

Mayo Clinic

The Journal of General Physiology | October 25, 2004 | Volume: 124 | Issue: 5 | Pages: 555-567

10.1085/jgp.200409077 | PMID 15504901 Get It

We examined functional contributions of interdomain contacts within the nicotinic receptor ligand binding site using single channel kinetic analyses, site-directed mutagenesis, and a homology model of the major extracellular region. At the principal face of the binding site, the invariant αD89 forms a highly conserved interdomain contact near αT148, αW149, and αT150. Patch-clamp recordings show that the mutation αD89N markedly slows acetylcholine (ACh) binding to receptors in the resting closed state, but does not affect rates of channel opening and closing. Neither αT148L, αT150A, nor mutations at both positions substantially affects the kinetics of receptor activation, showing that hydroxyl side chains at these positions are not hydrogen bond donors for the strong acceptor αD89. However substituting a negative charge at αT148, but not at αT150, counteracts the effect of αD89N, demonstrating that a negative charge in the region of interdomain contact confers rapid association of ACh. Interpreted within the structural framework of ACh binding protein and a homology model of the receptor ligand binding site, these results implicate main chain amide groups in the domain harboring αW149 as principal hydrogen bond donors for αD89. The specific effect of αD89N on ACh association suggests that interdomain hydrogen bonding positions αW149 for optimal interaction with ACh.
The Anti-thyroid Drug Methimazole Induces Neovascularization in the Neonatal Rat Analogous to ROP
Mookadam, Martina , Leske, David A. , Fautsch, Michael P. , Lanier, William L. , Holmes, Jonathan M. , Holmes, Jonathan M.

Mayo Clinic

Investigative Opthalmology & Visual Science | October 25, 2004 | Volume: 45 | Issue: 11 | Pages: 4145

10.1167/iovs.04-0675 | PMID 15505068 Get It

Corneal Reinnervation after LASIK: Prospective 3-Year Longitudinal Study
Calvillo, M., McLaren, Jay W. , Hodge, David O. , Bourne, William M.

Mayo Clinic

Investigative Opthalmology & Visual Science | October 25, 2004 | Volume: 45 | Issue: 11 | Pages: 3991

10.1167/iovs.04-0561 | PMID 15505047 Get It

TissueLink™ Device for Laparoscopic Nephron-Sparing Surgery
Stern, Jeffrey A., Simon, Scott D. , Ferrigni, Robert G., Andrews, Paul E.

Mayo Clinic

Journal of Endourology | October 22, 2004 | Volume: 18 | Issue: 5 | Pages: 455-456

10.1089/0892779041271463 | PMID 15253818 Get It

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Schilder, Russell J., Molina, Arturo , Bartlett, Nancy L. , Gordon, Leo I. , Murray, James L. , Spies, Stewart, Wiseman, Gregory A., Witzig, Thomas E. , Wang, Hua , White, Christine A. , Gordon, Leo I , Bartlett, Nancy L

Mayo Clinic

Cancer Biotherapy and Radiopharmaceuticals | October 22, 2004 | Volume: 19 | Issue: 4 | Pages: 478-481

10.1089/cbr.2004.19.478 | PMID 15453962 Get It